Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED)

U.S. stock futures rose on Monday following Friday's sharp sell-off, with major indices recovering from correction territory. President Trump suggested the U.S. could seize Iran's oil infrastructure while characterizing Iran's new leaders as 'very reasonable.' Markets are pricing in a 96.4% likelihood of unchanged Fed rates in April. Key movers include Palantir Technologies, Rezolve AI, and Entera Bio, while analyst Mohamed El-Erian warns of 'stagflationary winds' and economic headwinds ahead.

03/30/2026, 8:45 AM • Benzinga

Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In Focus

U.S. stock futures rose on Monday following Friday's sharp sell-off, with major indices recovering from correction territory. President Trump's comments about Iran's new leaders being 'very reasonable' and potential oil agreements provided some market optimism. Key movers included Palantir (partnership expansion), Rezolve AI (raised revenue outlook), and Entera Bio (earnings miss). Analysts warn of 'stagflationary winds' and expect continued volatility ahead.

03/30/2026, 5:27 AM • Benzinga

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

OPKO Health will report its financial results for Q4 and full year 2025 on February 26, 2026, followed by a conference call. The company has also expanded its partnership with Entera Bio to advance an oral long-acting PTH tablet for hypoparathyroidism treatment, marking the third successful program combining Entera's N-Tab platform with OPKO's protein chemistry capabilities.

02/12/2026, 8:00 AM • GlobeNewswire

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

OPKO Health and Entera Bio have expanded their collaboration to develop the first oral long-acting PTH analog for hypoparathyroidism treatment, aiming to file an IND application in late 2026. The companies will maintain equal 50/50 ownership and cost-sharing for this program. Additionally, they are advancing oral oxyntomodulin (dual GLP-1/glucagon analog) with Phase 1 injectable data expected by end of 2026. Steve Rubin from OPKO has joined Entera's board.

02/04/2026, 8:00 AM • GlobeNewswire

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

Entera Bio's CEO will participate in the Evercore ISI Healthcare Conference, highlighting the company's progress in developing oral peptide therapies for conditions like osteoporosis and hypoparathyroidism.

11/18/2025, 8:00 AM • GlobeNewswire

Entera Bio Beats Q2 EPS Estimates

Entera Bio reported better-than-expected Q2 2025 earnings with a GAAP EPS of $0.06, secured FDA regulatory concurrence for EB613's Phase 3 trial, and maintained a strong cash position of $18.8 million to support operations through mid-Q3 2026.

08/08/2025, 5:17 PM • The Motley Fool

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

OPKO Health, Inc. and Entera Bio Ltd. announced that OPKO's ModeX Therapeutics division has formed a Scientific Advisory Board with leaders in immunology and oncology drug development. Additionally, OPKO and Entera's first-in-class dual GLP-1/Glucagon tablet candidate for obesity and metabolic disorders has been selected for presentation at the ENDO 2025 Annual Meeting.

06/25/2025, 11:00 AM • GlobeNewswire